Investing.com - Compass Therapeutics, (NASDAQ: CMPX) reported fourth quarter EPS of $-0.10, $0.01 better than the analyst estimate of $-0.11. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Compass Therapeutics,'s stock price closed at $3.60. It is down -21.91% in the last 3 months and up 139.46% in the last 12 months.
Compass Therapeutics, saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Compass Therapeutics,'s stock price’s past reactions to earnings here.
According to InvestingPro, Compass Therapeutics,'s Financial Health score is "fair performance".
Check out Compass Therapeutics,'s recent earnings performance, and Compass Therapeutics,'s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar